These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22045759)

  • 1. FDA advisory decision highlights some problems inherent in pragmatic trials.
    Mitka M
    JAMA; 2011 Nov; 306(17):1851-2. PubMed ID: 22045759
    [No Abstract]   [Full Text] [Related]  

  • 2. New alternative to warfarin may help reduce stroke risk in patients with AF.
    Mitka M
    JAMA; 2011 Jan; 305(1):25-6. PubMed ID: 21205957
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.
    Fleming TR; Emerson SS
    N Engl J Med; 2011 Oct; 365(17):1557-9. PubMed ID: 21992495
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(6):342-3. PubMed ID: 21135986
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
    MMW Fortschr Med; 2013 Sep; 155(15):56-7. PubMed ID: 24224377
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    Brem E; Koyfman A; Foran M
    J Emerg Med; 2013 Jul; 45(1):143-9. PubMed ID: 23375217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Cardiology congress 2011.
    Cardiovasc J Afr; 2011; 22(5):287-8, 291-2. PubMed ID: 21983959
    [No Abstract]   [Full Text] [Related]  

  • 9. Raft of rivaroxaban good news from the USA, implications for South African clinical practice.
    Cardiovasc J Afr; 2011; 22(6):345-6. PubMed ID: 22159327
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants].
    Anisimova AV; Gendlin GE; Borisov SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(9 Pt 2):62-9. PubMed ID: 24107898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
    Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
    Simonyi G; Medvegy M
    Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
    Rajappan K
    Heart; 2013 Mar; 99(6):361-2. PubMed ID: 23024007
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation choices. Picking an anti-clotting drug.
    Mayo Clin Health Lett; 2014 Jun; 32(6):4-5. PubMed ID: 25029747
    [No Abstract]   [Full Text] [Related]  

  • 20. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS; Manolakos JJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.